Vertex Financial Statements From 2010 to 2024
| VX1 Stock | EUR 441.40 1.10 0.25% |
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
Vertex |
Vertex Pharmaceuticals Incorporated Company Return On Equity Analysis
Vertex Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Vertex Pharmaceuticals Return On Equity | 0.28 |
Most of Vertex Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vertex Pharmaceuticals Incorporated is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Vertex Pharmaceuticals Incorporated has a Return On Equity of 0.2767. This is 101.15% lower than that of the Healthcare sector and 100.76% lower than that of the Biotechnology industry. The return on equity for all Germany stocks is 189.26% lower than that of the firm.
Vertex Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Vertex Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Vertex Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vertex Pharmaceuticals competition to find correlations between indicators driving Vertex Pharmaceuticals's intrinsic value. More Info.Vertex Pharmaceuticals Incorporated is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.63 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Vertex Pharmaceuticals Incorporated is roughly 1.60 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vertex Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Vertex Pharmaceuticals Financial Statements
Vertex Pharmaceuticals stakeholders use historical fundamental indicators, such as Vertex Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Vertex Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Vertex Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Vertex Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Vertex Pharmaceuticals Incorporated. Please read more on our technical analysis and fundamental analysis pages.
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. VERTEX PHARMAC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 2500 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Vertex Stock
Vertex Pharmaceuticals financial ratios help investors to determine whether Vertex Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vertex with respect to the benefits of owning Vertex Pharmaceuticals security.